The reference standard for the confirmation of a recent rickettsial infection is by the observation of a four-fold or greater rise in antibody titres when testing paired acute and convalescent (two to four weeks after illness resolution) sera by serological assays (Figure 1 ). At the acute stage of illness, diagnosis is performed by molecular detection methods most effectively on DNA extracted from tissue biopsies (eschars, skin rash, and organs) or eschar swabs.
Less invasive and more convenient samples such as blood and serum may also be used for detection; however, the low number of circulating bacteria raises the possibility of false negative results. Optimal sampling practices and enhanced sensitivity must therefore be considered in order to provide a more accurate laboratory diagnosis. 
Timing of sample draw and antibiotic treatment
For the detection of rickettsial DNA in blood by molecular methods, the sample must be taken before or within 48 hours of appropriate antibiotic treatment to minimise false-negative results 2 . Note:
antibiotics must not be withheld and patients should be empirically treated upon suspicion of rickettsial infection. Due to the fast progression and potential severity of these diseases, early treatment is essential for the best possible outcome 
Assay sensitivity
Current molecular detection assays for rickettsial diseases include real-time PCR and isothermal amplification protocols with specificities varying from 78% to 99% and limits of detection from one to 10 copies per reaction 5 . These methodologies are at the limit of detection for these targets and technologies. This calculates to 200
to 2000 genome equivalents per millilitre of blood, which is still above the detection range needed (less than 100 copies per mL of blood) at the early stage of illness. Due to the variation in protocols it is unclear if the differences in sensitivities are due to amplification targets, reagents, instrumentation, extraction methodologies, or assessment strategies. RNA detection has increased the detectable range, as the target numbers may be higher than the DNA copies as long as labile RNA transcripts have not degraded.
Conclusion
There is currently an undefined level of accuracy for molecular detection methods in blood due to current DNA assay sensitivity and overall variation in best practices for sampling, stabilisation, and preparation. It is important to be mindful of the following when testing blood. (1) Draw sample during the symptomatic stage of illness, before or within 48 hours of doxycycline treatment. (2) Samples must be processed as soon as possible or within days to avoid template degradation, especially if EDTA is the blood stabiliser. (3) Assessment of alternative targets might increase assay sensitivity. RNA detection is a promising target and its utility and limitations are yet to be defined.
The optimisation of all preanalytical and analytical processes may improve rickettsial molecular detection in blood at the acute stage of illness. Further validation is needed to determine a standard for sample collection and handling to improve integrity of specimens suspected of rickettsial infection.
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